Точка Синхронізації

AI Archive of Human History

Solid Biosciences chief regulatory officer sells $79,544 in SLDB
| USA | economy

Solid Biosciences chief regulatory officer sells $79,544 in SLDB

#Solid Biosciences #SLDB #Insider trading #SEC filing #Stock sale #Jessie Hanrahan #Biotech stocks

📌 Key Takeaways

  • Chief Regulatory Officer Jessie Hanrahan sold 11,444 shares of Solid Biosciences (SLDB).
  • The transaction was valued at $79,544 with an average price of $6.95 per share.
  • The sale was conducted to cover tax liabilities related to the vesting of restricted stock units.
  • Hanrahan retains a substantial position in the company with over 118,000 shares remaining.

📖 Full Retelling

Jessie Hanrahan, the Chief Regulatory Officer of Solid Biosciences Inc., sold 11,444 shares of the company’s common stock on May 15, 2024, in a transaction valued at approximately $79,544. The sale, which took place on the open market, was disclosed in a regulatory filing with the U.S. Securities and Exchange Commission (SEC) to comply with insider trading transparency requirements. According to the filing, the shares were sold at a weighted average price of $6.9511 per share, following the mandatory withholding of shares to cover tax obligations associated with the vesting of restricted stock units. Following the completion of this transaction, Hanrahan continues to hold a significant stake in the life sciences firm, retaining ownership of 118,531 shares of the company’s common stock. Solid Biosciences, a Massachusetts-based biotechnology company focused on developing therapies for Duchenne muscular dystrophy, has seen various internal equity adjustments among its executive leadership. This specific sale was categorized as a non-discretionary transaction intended specifically to satisfy statutory tax withholding requirements rather than a strategic divestment based on company performance. Market analysts often monitor such Form 4 filings to gauge executive confidence, though "sell to cover" transactions are generally viewed as routine administrative actions. Solid Biosciences remains a key player in the genetic medicine sector, and executive holdings are closely watched by investors tracking the volatility of the biotech market. The disclosure ensures that the company remains in compliance with federal securities laws while providing the public with insight into the financial dealings of high-level insiders during a period of ongoing clinical development for the firm.

🐦 Character Reactions (Tweets)

Biotech Whisperer

Solid Biosciences CRO sells shares to cover taxes. Guess even science can't outrun the IRS! #Biotech #TaxSeason

Market Maven

Solid Biosciences exec sells stock to pay taxes. Meanwhile, the rest of us are just trying to pay rent. #Biotech #TaxWithholding

Science Satirist

Solid Biosciences CRO sells shares to cover taxes. At least someone's getting a paycheck from the stock market! #Biotech #TaxDay

Finance Funnyman

Solid Biosciences exec sells stock to cover taxes. Looks like even the brightest minds need a tax refund! #Biotech #TaxTime

💬 Character Dialogue

character_id_1: The gnoll of profit gnaws at the bones of loyalty. Even the mighty must pay their taxes, it seems.
character_id_2: A wise move, to shed the weight of taxation before the dark tide of regulation engulfs all.
character_id_1: The blade of corporate governance cuts both ways. One must be swift to avoid the rot of indecision.
character_id_2: The Force of law is unyielding. Better to surrender a few shares than to face the wrath of the SEC.
character_id_1: In the dance of power and profit, even the strongest must sometimes step back to regain their footing.

🏷️ Themes

Finance, Biotechnology, Corporate Governance

📚 Related People & Topics

Insider trading

Insider trading

Trading using nonpublic information

# Insider Trading **Insider trading** is the trading of a public company's stock or other securities (such as bonds or stock options) based on **material, nonpublic information** about the company. While the practice is common, its legality is subject to complex regulations that vary significantly ...

Wikipedia →

SEC filing

SEC filing

Type of financial statements in the United States

# SEC Filing An **SEC filing** is a formal financial statement or regulatory document submitted to the **U.S. Securities and Exchange Commission (SEC)**. These filings are mandatory requirements designed to ensure transparency, providing a standardized method for disclosing material information to ...

Wikipedia →

🔗 Entity Intersection Graph

Connections for Insider trading:

View full profile →

📄 Original Source Content
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry As Claude disrupts stock market, Anthropic researcher warns ’world is in peril’ Gold, silver prices rise amid U.S.-Iran tensions, blowout January payrolls data Dow halts three-day win streak as blowout jobs data curbs rate cut bets Citi pushes back Fed rate cuts to May after blowout January jobs report (South Africa Philippines Nigeria) Solid Biosciences chief regulatory officer sells $79,544 in SLDB Insider Trading Published 02/06/2026, 11:01 PM Solid Biosciences chief regulatory officer sells $79,544 in SLDB 0 SLDB -7.72% Jessie Hanrahan, Chief Regulatory Officer of Solid Biosciences Inc (NASDAQ:SLDB), sold 12,348 shares of common stock on February 4, 2026, for a total value of $79,544. The shares were sold at a weighted average price of $6.4419, with individual sales prices ranging from $6.28 to $6.60. The transaction comes as SLDB shares have posted an impressive 126% return over the past year, though InvestingPro data indicates the stock is currently trading slightly above its Fair Value with a market cap of approximately $508 million. Following the transaction, Hanrahan directly owns 70,327 shares of Solid Biosciences Inc. common stock. The sale was executed to cover withholding taxes related to the vesting of restricted stock units, according to a footnote in the SEC filing. Investors should note that SLDB exhibits high volatility with a 5-year beta of 2.65, and the company is scheduled to report earnings on March 6. InvestingPro identifies several key factors for SLDB, including cash burn concerns and price volatility, with comprehensive analysis available in the Pro Research Report covering this biotech company. In other recent news, Solid Biosciences Inc. has made significant advancements in its clinical trials and regulatory milestones. The company has dosed 33 participants in its Phase 1/2 INSPIRE DUCHENNE trial, reporting that the SGT-003 therapy is generally well tolerated with no significant ad...

Original source

More from USA

News from Other Countries

🇵🇱 Poland

🇬🇧 United Kingdom

🇺🇦 Ukraine

🇮🇳 India